[go: up one dir, main page]

HRP20020171A2 - Use of docetaxel for treating hepatocellular carcinoma - Google Patents

Use of docetaxel for treating hepatocellular carcinoma Download PDF

Info

Publication number
HRP20020171A2
HRP20020171A2 HR20020171A HRP20020171A HRP20020171A2 HR P20020171 A2 HRP20020171 A2 HR P20020171A2 HR 20020171 A HR20020171 A HR 20020171A HR P20020171 A HRP20020171 A HR P20020171A HR P20020171 A2 HRP20020171 A2 HR P20020171A2
Authority
HR
Croatia
Prior art keywords
docetaxel
cells
paclitaxel
hours
treatment
Prior art date
Application number
HR20020171A
Other languages
English (en)
Croatian (hr)
Inventor
Chin-Wen Chi
Heng-Liang Lin
Tsung-Yun Liu
Wing-Yiu Lui
Gar-Yang Chau
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of HRP20020171A2 publication Critical patent/HRP20020171A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
HR20020171A 1999-08-31 2000-08-29 Use of docetaxel for treating hepatocellular carcinoma HRP20020171A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9920548.6A GB9920548D0 (en) 1999-08-31 1999-08-31 Treatment of hepatocellular carcinoma
PCT/EP2000/008782 WO2001015675A2 (en) 1999-08-31 2000-08-29 Use of docetaxel for treating hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
HRP20020171A2 true HRP20020171A2 (en) 2004-02-29

Family

ID=10860081

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020171A HRP20020171A2 (en) 1999-08-31 2000-08-29 Use of docetaxel for treating hepatocellular carcinoma

Country Status (34)

Country Link
US (2) US20030158249A1 (xx)
EP (1) EP1214061B1 (xx)
JP (1) JP4866522B2 (xx)
KR (1) KR100670416B1 (xx)
CN (1) CN1174748C (xx)
AT (1) ATE269700T1 (xx)
AU (1) AU777583B2 (xx)
BG (1) BG65913B1 (xx)
BR (1) BR0013625A (xx)
CA (1) CA2382294C (xx)
CZ (1) CZ301378B6 (xx)
DE (1) DE60011794T2 (xx)
DK (1) DK1214061T3 (xx)
EA (1) EA004804B1 (xx)
EE (1) EE05124B1 (xx)
ES (1) ES2218223T3 (xx)
GB (1) GB9920548D0 (xx)
HK (1) HK1048944B (xx)
HR (1) HRP20020171A2 (xx)
HU (1) HU228861B1 (xx)
IL (2) IL147489A0 (xx)
ME (1) MEP7809A (xx)
MX (1) MXPA02002041A (xx)
NO (1) NO328527B1 (xx)
NZ (1) NZ517604A (xx)
PL (1) PL212612B1 (xx)
PT (1) PT1214061E (xx)
RS (1) RS50148B (xx)
SI (1) SI1214061T1 (xx)
SK (1) SK286378B6 (xx)
TW (1) TW589180B (xx)
UA (1) UA72927C2 (xx)
WO (1) WO2001015675A2 (xx)
ZA (1) ZA200201408B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268619C (zh) 2003-05-08 2006-08-09 上海迪赛诺化学制药有限公司 多烯紫杉醇三水化合物的制备方法
WO2005061474A1 (en) * 2003-12-12 2005-07-07 Quiral Química Do Brasil Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
NO345390B1 (no) 2005-08-31 2021-01-11 Abraxis Bioscience Llc Preparater omfattende dårlig vannløselige farmasøytiske midler og antimikrobielle midler
NZ592132A (en) * 2005-08-31 2012-12-21 Abraxis Bioscience Llc Composition comprising nanoparticles of docitaxel and a citrate
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
CN102014918A (zh) * 2007-04-20 2011-04-13 太阳医药工业有限公司 由微量沉淀产生的药学组合物
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
HUE027749T2 (en) 2010-03-26 2016-10-28 Abraxis Bioscience Llc Methods of treating hepatocellular carcinoma
CA2798180A1 (en) * 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
WO2016134066A1 (en) * 2015-02-17 2016-08-25 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2629819B1 (fr) * 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
EP0680320B1 (en) * 1993-01-19 1999-04-14 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
US5801029A (en) * 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
DE69737510T2 (de) * 1996-12-30 2007-12-06 Battelle Memorial Institute, Columbus Verwendung eines unverkapselten Antikrebs-Arzneimittels zur Herstellung einer Zubereitung zur Behandlung von Neoplasmen durch Inhalation
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
PT1023050E (pt) * 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
ATE233104T1 (de) * 1997-09-18 2003-03-15 Janssen Pharmaceutica Nv Kondensierte imidazolderivate zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
US6576660B1 (en) * 1997-10-31 2003-06-10 Arch Development Corporation Methods and compositions for regulation of 5-α-reductase activity
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
JP2002533407A (ja) * 1998-12-23 2002-10-08 ジー・ディー・サール・アンド・カンパニー 新形成の治療におけるマトリクスメタロプロテイナーゼ阻害剤とインテグリン拮抗剤の使用
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
CN101370774A (zh) * 2005-12-13 2009-02-18 特瓦制药工业有限公司 阿托伐他汀半钙的晶形及其制备方法

Also Published As

Publication number Publication date
PL212612B1 (pl) 2012-10-31
ME00624B (me) 2011-12-20
NZ517604A (en) 2004-04-30
EA200200313A1 (ru) 2002-08-29
EE05124B1 (et) 2009-02-16
ES2218223T3 (es) 2004-11-16
KR100670416B1 (ko) 2007-01-17
CN1372466A (zh) 2002-10-02
CA2382294C (en) 2008-06-03
WO2001015675A3 (en) 2001-09-20
EP1214061A2 (en) 2002-06-19
ZA200201408B (en) 2003-07-30
KR20020060166A (ko) 2002-07-16
HUP0203197A3 (en) 2005-01-28
CZ2002739A3 (cs) 2002-06-12
EA004804B1 (ru) 2004-08-26
DE60011794D1 (de) 2004-07-29
NO20020829D0 (no) 2002-02-20
PT1214061E (pt) 2004-09-30
SK286378B6 (sk) 2008-08-05
DE60011794T2 (de) 2005-07-14
MEP7809A (en) 2011-12-20
AU777583B2 (en) 2004-10-21
CZ301378B6 (cs) 2010-02-03
IL147489A0 (en) 2002-08-14
RS50148B (sr) 2009-05-06
GB9920548D0 (en) 1999-11-03
BG106460A (bg) 2002-09-30
MXPA02002041A (es) 2002-08-20
CN1174748C (zh) 2004-11-10
HK1048944A1 (en) 2003-04-25
HUP0203197A2 (hu) 2003-01-28
US20080045584A1 (en) 2008-02-21
WO2001015675A2 (en) 2001-03-08
SK2712002A3 (en) 2002-07-02
ATE269700T1 (de) 2004-07-15
AU7516800A (en) 2001-03-26
SI1214061T1 (en) 2004-12-31
BR0013625A (pt) 2002-05-14
EP1214061B1 (en) 2004-06-23
CA2382294A1 (en) 2001-03-08
PL353198A1 (en) 2003-11-03
HK1048944B (zh) 2005-04-22
IL147489A (en) 2006-06-11
NO20020829L (no) 2002-02-20
TW589180B (en) 2004-06-01
EE200200087A (et) 2003-04-15
JP4866522B2 (ja) 2012-02-01
UA72927C2 (uk) 2005-05-16
NO328527B1 (no) 2010-03-08
DK1214061T3 (da) 2004-11-01
YU11402A (sh) 2005-07-19
US20030158249A1 (en) 2003-08-21
BG65913B1 (bg) 2010-05-31
HU228861B1 (hu) 2013-06-28
JP2003508427A (ja) 2003-03-04

Similar Documents

Publication Publication Date Title
US20080045584A1 (en) Use of Docetaxel for Treating Hepatocellular Carcinoma
CN1845757B (zh) 细胞因子混合物在制备由于预敏化癌症的药物中的用途和用于治疗癌症的药物组合物
US20220133675A1 (en) Phorbol ester compositions and methods of use for treating or reducing the duration of cytopenia
US20150110774A1 (en) S100 protein inhibitors for treating leukemia
US8580847B2 (en) Antrocin containing pharmaceutical compositions for inhibiting cancer cells
WO2004091661A1 (ja) 糖尿病治療剤
US20200316131A1 (en) Pharmaceutical composition for treating drug-resistant cancer comprising exosomes derived from differentiating stem cells as an active ingredient
de Haan et al. Hemotoxicity by prolonged etoposide administration to mice can be prevented by simultaneous growth factor therapy
Horoszewicz et al. The Colony-Forming Cell in the Normal and Leukemic Human Host: Responses to Streptovaricin and Rifamycin SV
Khudhair et al. Ameliorative Effects of Lutein Supplementation against Cardio-toxicity Induced by Ciprofloxacin and Daunorubicin: in Rats
WO2023160112A1 (zh) 嗜氮酮类化合物及其在制备抗肿瘤药物中的用途
KR20070108933A (ko) 알부민 결합성 약물의 안전성 및 효능을 증가시키는 방법및 조성물
HK1105858A (en) A method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture
HK1096846A (en) A method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20070801

Year of fee payment: 8

ODBI Application refused